Company intelligence / Profile preview
ALT5 Sigma
Las Vegas, Nevada, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
ALT5 Sigma is developing JAN 101 (oral sodium nitrite, completed Phase 2a for peripheral arterial disease and pain), and JAN123 (low-dose naltrexone for chronic regional pain syndrome). No published Phase 3 or NDA/approval data.
- Therapeutic areas
- CardiovascularNeurologyPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on ALT5 Sigma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALT5 Sigma.